{
    "clinical_study": {
        "@rank": "25205", 
        "acronym": "Restore", 
        "arm_group": {
            "arm_group_label": "Post-abiraterone or post-enzalutamide", 
            "arm_group_type": "Experimental", 
            "description": "Men with castration-resistant prostate cancer who have progressed on either abiraterone or enzalutamide will be enrolled to this arm. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with either abiraterone 1000 mg by mouth daily or enzalutamide 160 mg by mouth daily, depending on which drug they previously received."
        }, 
        "brief_summary": {
            "textblock": "Single-arm, single site, open label study of the effects of parenteral testosterone followed\n      by enzalutamide or abiraterone in men with metastatic CRPC who previously progressed on\n      either of these agents. The study will enroll two cohorts of patients: men with metastatic\n      CRPC who have progressed on enzalutamide (Cohort A); and men with metastatic CRPC who have\n      progressed on abiraterone acetate (Cohort B)."
        }, 
        "brief_title": "RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study)", 
        "completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The trial will enroll up to 60 patients, 30 for each cohort. Eligible patients will continue\n      on androgen ablative therapy with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron)\n      if not surgically castrated to suppress endogenous testosterone production. Patients will\n      also receive intramuscular injection with either testosterone cypionate or testosterone\n      enanthate at a dose of 400 mg every 28 days. This dosing scheme was designed to produce\n      rapidly fluctuating serum testosterone levels from the supraphysiologic to the near-castrate\n      range (i.e. Bipolar Androgen Therapy [BAT]). Assessments for response to testosterone will\n      be made approximately every 3 months. Upon displaying evidence of progression, patients will\n      then go on to receive either abiraterone or enzalutamide (whichever agent they had\n      previously progressed on prior to study enrollment)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Performance status \u22642\n\n          2. Age \u226518 years\n\n          3. Histologically-confirmed adenocarcinoma of the prostate\n\n          4. Treated with continuous androgen ablative therapy (either surgical castration or LHRH\n             agonist)\n\n          5. Documented castrate level of serum testosterone (<20 ng/dl)\n\n          6. Must have progressed on prior treatment with enzalutamide or abiraterone acetate +\n             prednisone (by PSA criteria or radiographically).\n\n          7. Patients with rising PSA on two successive measurements at least two weeks apart\n\n          8. Prior treatment with up to 2 additional second line hormone therapies, including\n             ketoconazole is allowed.\n\n          9. Patients who have progressed on both enzalutamide and abiraterone acetate are\n             eligible and post-BAT will be retreated with the last second line agent they had\n             received (e.g. patient receiving abiraterone then enzalutamide would receive\n             retreatment with enzalutamide post-BAT).\n\n         10. Patients must be withdrawn from enzalutamide or abiraterone acetate for \u2265 4 weeks and\n             have documented PSA increase after the withdrawal period.\n\n         11. Patients receiving prednisone in conjunction with abiraterone acetate must be weaned\n             off prednisone prior to starting BAT.\n\n         12. Acceptable liver function:\n\n               1. Bilirubin < 2.5 times institutional upper limit of normal (ULN)\n\n               2. AST (SGOT) and ALT (SGPT) < 2.5 times ULN\n\n         13. Acceptable renal function:\n\n             a.Serum creatinine < 2.5 times ULN, OR\n\n         14. Acceptable hematologic status:\n\n               1. Absolute neutrophil count (ANC) \u2265 1500 cells/mm3 (1.5 \u00d7109/L)\n\n               2. Platelet count \u2265 100,000 platelet/mm3 (100 \u00d7109/L)\n\n               3. Hemoglobin \u2265 9 g/dL.\n\n         15. At least 4 weeks since prior surgery with full recovery (no persistent toxicity \u2265\n             Grade 1)\n\n         16. Ability to understand and willingness to sign a written informed consent document.\n\n        Exclusion Criteria:\n\n          1. Pain due to metastatic prostate cancer requiring opioid analgesics\n\n          2. >5 sites of visceral disease in lung or liver (nonspecific lung nodules \u22641 cm in\n             diameter are permitted).\n\n          3. Prior treatment with docetaxel or cabazitaxel.\n\n          4. Prior seizures while on enzalutamide therapy.\n\n          5. Requires urinary catheterization for voiding due to obstruction secondary to\n             prostatic enlargement thought to be due to prostate cancer or benign prostatic\n             hyperplasia.\n\n          6. Evidence of disease in sites or extent that, in the opinion of the investigator,\n             would put the patient at risk from therapy with testosterone (e.g. femoral metastases\n             with concern over fracture risk, spinal metastases with concern over spinal cord\n             compression, lymph node disease with concern for ureteral obstruction).\n\n          7. Evidence of serious and/or unstable pre-existing medical, psychiatric or other\n             condition (including laboratory abnormalities) that could interfere with patient\n             safety or provision  of informed consent to participate in this study\n\n          8. Active uncontrolled infection, including known history of AIDS or hepatitis B or C.\n\n          9. Prior history of a thromboembolic event within the last two years and not currently\n             on systemic anticoagulation.\n\n         10. Prior myocardial infarction within one year of study entry.\n\n         11. Hematocrit >50%, untreated severe obstructive sleep apnea, uncontrolled or poorly\n             controlled heart failure [per Endocrine Society Clinical Practice Guidelines (67)].\n\n         12. Any psychological, familial, sociological, or geographical condition that could\n             potentially interfere with compliance with the study protocol and follow-up schedule."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02090114", 
            "org_study_id": "J1416", 
            "secondary_id": "NA_00093344"
        }, 
        "intervention": [
            {
                "arm_group_label": "Post-abiraterone or post-enzalutamide", 
                "description": "DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.", 
                "intervention_name": "Testosterone cypionate", 
                "intervention_type": "Drug", 
                "other_name": "DEPO-Testosterone Injection"
            }, 
            {
                "arm_group_label": "Post-abiraterone or post-enzalutamide", 
                "description": "Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL  contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.", 
                "intervention_name": "Testosterone Enanthate", 
                "intervention_type": "Drug", 
                "other_name": "Delatestryl"
            }, 
            {
                "arm_group_label": "Post-abiraterone or post-enzalutamide", 
                "description": "Abiraterone is an inhibitor of CYP17 (17\u03b1-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.", 
                "intervention_name": "Abiraterone acetate", 
                "intervention_type": "Drug", 
                "other_name": "Zytiga"
            }, 
            {
                "arm_group_label": "Post-abiraterone or post-enzalutamide", 
                "description": "XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.", 
                "intervention_name": "Enzalutamide", 
                "intervention_type": "Drug", 
                "other_name": "Xtandi"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Androgens", 
                "Methyltestosterone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Bipolar Androgen Therapy", 
            "Testosterone", 
            "Enzalutamide", 
            "Abiraterone", 
            "Androgen Ablative Therapies"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "location": {
            "contact": {
                "email": "aspitz2@jhmi.edu", 
                "last_name": "Avery Spitz", 
                "phone": "410-502-2043"
            }, 
            "contact_backup": {
                "email": "tomalra@jhmi.edu", 
                "last_name": "Rana Sullivan", 
                "phone": "410-614-6337"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21231"
                }, 
                "name": "The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
            }, 
            "investigator": {
                "last_name": "Samuel Denmeade, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies", 
        "overall_contact": {
            "email": "aspitz2@jhmi.edu", 
            "last_name": "Avery Spitz", 
            "phone": "410-502-2043"
        }, 
        "overall_contact_backup": {
            "email": "tomalra@jhmi.edu", 
            "last_name": "Rana Sullivan", 
            "phone": "410-614-6337"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center", 
            "last_name": "Samuel Denmeade, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "PSA response to BAT (\u226550% PSA reduction from pre-BAT baseline level).", 
                "measure": "PSA response to Bipolar Androgen Therapy", 
                "safety_issue": "Yes", 
                "time_frame": "On average at 18 months"
            }, 
            {
                "description": "PSA response to enzalutamide or abiraterone acetate post-BAT (\u226550% PSA reduction from baseline PSA level obtained at initiation of enzalutamide or abiraterone acetate post-BAT)", 
                "measure": "PSA response to enzalutamide or abiraterone acetate post Bipolar Androgen Therapy", 
                "safety_issue": "No", 
                "time_frame": "On average at 24 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02090114"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time to PSA progression on enzalutamide or abiraterone acetate post-BAT", 
                "measure": "PSA progression on enzalutamide or abiraterone acetate post-BAT", 
                "safety_issue": "No", 
                "time_frame": "On average at 18 months"
            }, 
            {
                "description": "Time to PSA progression on BAT", 
                "measure": "PSA progression on BAT (Bipolar Androgen Therapy )", 
                "safety_issue": "No", 
                "time_frame": "On average at 18 months"
            }, 
            {
                "description": "Measurable disease response post-BAT and post-treatment with enzalutamide or abiraterone acetate post-BAT.\nFor soft tissue lesions, based on RECIST 1.1.\nFor bone disease, based on PCWG2 criteria.", 
                "measure": "Measurable disease response", 
                "safety_issue": "Yes", 
                "time_frame": "On average at 18 months"
            }, 
            {
                "description": "Time to initiation of docetaxel chemotherapy", 
                "measure": "initiation of docetaxel chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "On average at 18 months"
            }, 
            {
                "description": "The following quality of life surveys will be administered: FACIT-F, RANDSF-36, Brief Pain Inventory, IIEF and PANAS,", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "On average at 18 months"
            }, 
            {
                "description": "Adverse events will be collected at each clinic visit and classified for severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0.", 
                "measure": "Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "On average at 18 months"
            }, 
            {
                "description": "Fasting blood glucose level", 
                "measure": "Fasting glucose", 
                "safety_issue": "No", 
                "time_frame": "On average at 18 months"
            }, 
            {
                "description": "hemoglobin A1c level", 
                "measure": "hemoglobin A1c", 
                "safety_issue": "No", 
                "time_frame": "On average at 18 months"
            }, 
            {
                "description": "Fasting insulin levels", 
                "measure": "Fasting insulin", 
                "safety_issue": "No", 
                "time_frame": "On average at 18 months"
            }, 
            {
                "description": "Serum N-telopeptide levels", 
                "measure": "Serum N-telopeptide", 
                "safety_issue": "No", 
                "time_frame": "On average at 18 months"
            }, 
            {
                "description": "Osteocalcin levels", 
                "measure": "Osteocalcin", 
                "safety_issue": "No", 
                "time_frame": "On average at 18 months"
            }
        ], 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}